{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:54:34Z","timestamp":1769604874936,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.eplepsyres.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T17:36:32Z","timestamp":1528133792000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program"],"prefix":"10.1016","volume":"145","author":[{"given":"Martin J.","family":"Brodie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toufic","family":"Fakhoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anny-Odile","family":"Colson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-5264","authenticated-orcid":false,"given":"Armel","family":"Stockis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Elmoufti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Whitesides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0010","first-page":"295","article-title":"Carbamazepine: biotransformation","volume":"11","author":"Frigerio","year":"1975","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pds.1871","article-title":"Antiepileptic drugs in Australia: 2002\u20132007","volume":"19","author":"Hollingworth","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eplepsyres.2011.05.003","article-title":"Trends in the use of antiepileptic drugs in Taiwan from 2003 to 2007: a population-based national health insurance study","volume":"96","author":"Hsieh","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0030","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","article-title":"Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population","volume":"95","author":"Landmark","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2125.1981.tb01851.x","article-title":"Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients","volume":"12","author":"MacKichan","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.nrl.2014.09.005","article-title":"Anticonvulsant prescription patterns in patients covered by the Colombian Health System","volume":"32","author":"Morales-Plaza","year":"2017","journal-title":"Neurologia"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0050","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","article-title":"Trends in antiepileptic drug utilisation in UK primary care 1993\u20132008: cohort study using the general practice research database","volume":"21","author":"Nicholas","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0055","series-title":"Tegretol Tablets 100\u202fmg, 200\u202fmg, 400\u202fmg Summary of Product Characteristics","author":"Novartis","year":"2015"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0060","series-title":"Presented at the 69th Annual American Epilepsy Society Meeting","article-title":"Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures, abstract No 1.219","author":"Otoul","year":"2015"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(85)90420-9","article-title":"Side-effects induced by carbamazepine-10,11-epoxide","author":"Patsalos","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0070","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs \u2212 best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0075","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1528-1157.1993.tb02117.x","article-title":"Carbamazepine-valnoctamide interaction in epileptic patients: in vitro\/in vivo correlation","volume":"34","author":"Pisani","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0080","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00007691-198412000-00005","article-title":"Free and total plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients: diurnal fluctuations and relationship with side effects","volume":"6","author":"Riva","year":"1984","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0090","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1469-8749.1984.tb08169.x","article-title":"Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy","volume":"26","author":"Schoeman","year":"1984","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0095","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007691-199412000-00001","article-title":"Carbamazepine and its epoxide: an open study of efficacy and side effects after carbamazepine dose increment in refractory partial epilepsy","volume":"16","author":"Semah","year":"1994","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eplepsyres.2015.03.003","article-title":"Brivaracetam and carbamazepine interaction in healthy subjects and in vitro","volume":"113","author":"Stockis","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eplepsyres.2016.11.001","article-title":"Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration","volume":"128","author":"Stockis","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00007691-199612000-00006","article-title":"Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication","volume":"18","author":"Svinarov","year":"1996","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archneur.1984.04210080006004","article-title":"Potent therapeutic effect of carbamazepine-10,11-epoxide in trigeminal neuralgia","volume":"41","author":"Tomson","year":"1984","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0120","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/archneur.1990.00530080072013","article-title":"Carbamazepine-10,11-epoxide in epilepsy a pilot study","volume":"47","author":"Tomson","year":"1990","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0920-1211(92)90049-Y","article-title":"Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide","volume":"11","author":"Warner","year":"1992","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.06.002_bib0130","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1081\/CLT-120015836","article-title":"Carbamazepine poisoning: elimination kinetics and quantitative relationship with carbamazepine 10,11-epoxide","volume":"40","author":"Winnicka","year":"2002","journal-title":"J. Toxicol. Clin. Toxicol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117303078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121117303078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:39:34Z","timestamp":1760276374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121117303078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":26,"alternative-id":["S0920121117303078"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.06.002","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}